Alendronic acid

Generic Name: Alendronic acid

Brand Names: Adrovance, Binosto, Fosamax, Fosamax Plus D, Fosavance

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₃NO_₇P_₂

CAS Number: 66376-36-1

Unique Ingredient Identifier: X1J18R4W8P

Background: Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.

Indication: Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.

Associated Conditions: Osteogenesis Imperfecta (OI), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget’s Disease

Associated Therapies: -

Clinical Trials

Local Host Modulating Agents Alendronate & Aloe Vera for Treatment of Furcation Defects in Chronic Periodontitis

Phase 2

Completed

Conditions: Chronic Periodontitis

Interventions: Drug: placebo
Drug: Alendronate
Drug: Aloe Vera

First Posted Date: 2017-06-29

Last Posted Date: 2017-06-29

Lead Sponsor: Government Dental College and Research Institute, Bangalore

Target Recruit Count: 90

Registration Number: NCT03204097

Osteoporosis Treatment in Post-menopausal Women

Phase 4

Conditions: Depressive Syndrome

Interventions: Drug: Raloxifene
Drug: Alendronate

First Posted Date: 2016-12-30

Last Posted Date: 2019-01-14

Lead Sponsor: Taichung Veterans General Hospital

Target Recruit Count: 500

Registration Number: NCT03006003

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳
outpatient clinic of the Division of Endocrinology and Metabolism in Taichung Veterans General Hospital, Taichung, Taiwan

Denosumab Versus Bisphosphonates (Alendronate) in GIOP

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: Denosumab
Drug: Alendronate

First Posted Date: 2016-12-29

Last Posted Date: 2020-02-12

Lead Sponsor: Tuen Mun Hospital

Target Recruit Count: 140

Registration Number: NCT03005678

Locations: 🇨🇳
Department of Medicine, Tuen Mun Hospital, Hong Kong, China

Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis
Osteoporosis

Interventions: Drug: Placebo
Drug: Alendronate
Drug: Calcium
Drug: Vitamin D

First Posted Date: 2016-10-26

Last Posted Date: 2023-11-27

Lead Sponsor: University of Aarhus

Target Recruit Count: 69

Registration Number: NCT02944799

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰
Hjørring Hospital, Hjørring, Denmark
🇩🇰
Vejle Hospital, Vejle, Denmark

and more 3 locations

Pilot Study of Bisphosphonates for Breast Cancer

Phase 1

Terminated

Conditions: Breast Neoplasms

Interventions: Drug: Alendronate

First Posted Date: 2016-05-24

Last Posted Date: 2020-10-22

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 6

Registration Number: NCT02781805

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis

Phase 4

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: Alendronate
Drug: Ibandronate

First Posted Date: 2015-11-05

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 341

Registration Number: NCT02598440

Renal Osteodystrophy: An Individual Management Approach

Not Applicable

Completed

Conditions: Kidney Failure, Chronic

Interventions: Drug: Alendronate
Drug: Teriparatide
Drug: Cinacalcet

First Posted Date: 2015-05-12

Last Posted Date: 2023-01-05

Lead Sponsor: Hartmut Malluche, MD

Target Recruit Count: 141

Registration Number: NCT02440581

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism

Phase 4

Completed

Conditions: Hyperparathyroidism, Primary
Osteoporosis

Interventions: Drug: cinacalcet
Drug: Alendronate

First Posted Date: 2015-04-15

Last Posted Date: 2015-04-15

Lead Sponsor: Istituto Auxologico Italiano

Target Recruit Count: 22

Registration Number: NCT02417389

Locations: 🇮🇹
Istituto Auxologico Italiano IRCCS, Milano, Italy

The Forteo Alendronate Comparator Trial

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: Teriparatide
Drug: Alendronate
Dietary Supplement: Calcium
Dietary Supplement: Vitamin D
Drug: Placebo-Oral
Drug: Placebo-SC

First Posted Date: 2015-04-14

Last Posted Date: 2015-04-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 203

Registration Number: NCT02416271

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss

Phase 4

Terminated

Conditions: Bone Demineralization

Interventions: Drug: Alendronate
Drug: Placebo
Dietary Supplement: calcium carbonate and colecalciferol
Drug: Tenofovir disoproxil

First Posted Date: 2014-12-22

Last Posted Date: 2022-05-26

Lead Sponsor: University College Dublin

Target Recruit Count: 53

Registration Number: NCT02322099

Locations: 🇮🇪
Beaumont Hospital, Dublin, Ireland
🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy